37 results about "Loss of function mutation" patented technology

The invention relates to construction of rice transgenic materials and aims to provide a gene editing method for knocking out rice MIRNA393b stem-loop sequences with application of a CRISPR(clustered regulatory interspersed short palindromic repeat)-Cas9 system. The gene editing method comprises steps as follows: gRNA target sites are selected for cloning and GG linking, enzyme digestion is performed after amplification, and a product is linked with a pGREB 32 vector; escherichia coli competent cells are transformed; plasmids with a correct sequencing result are used for transforming agrobacteria, transgenic plants are obtained through mediated transformation of rice calli, and transgenic positive lines are obtained; the T0-generation mutant plant seeds are collected for seeding, and the T1-generation plants are subjected to homozygote screening; homozygous lines which are discovered to be negative through MIRNA393b expression are rice mutants completely losing the MIRNA393b stem-loop sequences and MIRNA393b stem-loop sequence expression. According to the gene editing method, MIRNA stem-loop sequences can be effectively knocked out, and loss-of-function mutants of different members in the same MIRNA family can be prepared; the mutant plant propagates to obtain a large number of seeds and is an ideal material for acquiring rice MIRNA393b gene functions successfully.

[Problem]

Providing soybean including oleic acid that will exceed the heretofore developed high-oleic soybean without using gene engineering technology.

[Means to Solve the Problem]

The present invention provides a GmFAD2-1b gene loss of function mutation and a type of soybean that includes a GmGAD2-1b gene loss of function mutation.

The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K⁺ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.

The present invention relates to compositions and methods of diagnosing and treating autoimmune and inflammatory disorders that are characterized by IL-23R loss-of-function mutations.

The invention provides cloning and application of flowering period BnFLC.A2 and Bnflc.a2 genes of brassica napus, and particularly provides isolation cloning, functional verification and application of two DNA fragments of an early flowering Bnflc.a2 gene and a later flowering BnFLC.A2 allele of rape. The early flowering Bnflc.a2 allogene is a loss-of-function mutant of the BnFLC.A2 gene. A functional marker of the early flowering gene is developed; the Bnflc.a2 gene has remarkable influence on the flowering period in a natural population under seven environments through the natural population genotype and flowering period phenotypic analysis of 495 portions of brassica napus, which shows that the copy function loss caused by the insertion of long fragments in the Bnflc.a2 is an important factor influencing the natural variation of the flowering time of the brassica napus. A serial design functional marker of the Bnflc.a2 itself is used for carrying out assisted selection of molecular markers and breeding early-flowering materials, thereby breeding early-flowering and early-maturing rape. The invention has the characteristics of accuracy, high efficiency and economy.

The invention is directed to a method for non-invasive determination of the potential presence of one or more loss-of-function mutation(s) in the gene encoding for filaggrin.

The method of the invention comprises

• (i) obtaining a vibrational spectrum from the stratum corneum of the individual;
• (ii) determining the local natural moisturising factor content from the vibrational spectrum;
• (iii) optionally repeating steps (i) and (ii); and
• (iv) comparing the local natural moisturising factor content of the individual to a reference value,
• wherein said stratum corneum is stratum corneum of a location of the body of said individual at which said one or more loss-of-function mutation(s) in the gene encoding for filaggrin has a stronger influence on the natural moisturising factor concentration than other factors influencing the natural moisturising factor concentration.

Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.

The present invention uses an isolated polynucleotide having a part or whole of GFRA1 gene, mutant GFRA1 protein, and mRNA encoding the mutant GFRA1 protein, each of which includes a loss-of-function mutation of GFRA1, as markers for diagnosing an animal as affected by forelimb-girdle muscular anomaly or as a carrier of forelimb-girdle muscular anomaly. In addition, an isolated polynucleotide comprising one or more selected from the group consisting of MOK2630, MOK2637, SNP B, and SNP D can be used as markers for diagnosing whether a bovine animal is affected by forelimb-girdle muscular anomaly or whether a bovine animal is a carrier of forelimb-girdle muscular anomaly.

The present invention provides for a method for screening for gene function for a bacteriophage, the method comprising: (1) (a) providing one or more host organism, such as a species or strain, libraries, (b) providing randomly barcoded transposon sequencing (such as RB-TnSeq), and (c) screening for loss-of-function (LOF) mutant phenotypes; or (2) (a) providing one or more DNA barcoded overexpression strain libraries (such as Dub-seq) using DNA of the host organism and/or phage, and (b) screening for gain-of-function (GOF).

The invention relate to the technical field of plant genetic breeding, in particular to a construction method of an activation tag carrier and apocynum venetum seed mutant library. Compared with the prior art, a large-scale apocynum venetum mutant seed group can be rapidly obtained through selection of explants, genetic transformation and construction of a regeneration system; an activation tag sequence in the mutant group comprises four series-connected 35s enhancers, activation tags are randomly distributed in the overall apocynum venetum genome, expression of adjacent genes is enhanced, mutants are formed by induction, the produced mutants are in dominant mutation, and lethal effect produced by loss-of-function mutation is avoided.

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a rapamycin analog would produce an anti-cancer effect in a subject. It is based, at least in part, on the results of experiments employing an integrated next-generation sequencing approach to interrogate spatially separated tumor specimens from the same individuals to decipher intra-tumor and intertumor heterogeneity and determine the oncogenomic basis of exceptional therapeutic benefit to rapalogs in kidney cancer patients. These experiments implicated loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR in therapeutic responsiveness to rapamycin analogs. Accordingly, in non-limiting embodiments, the present invention provides for assay methods and kits for determining the presence of loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR, and methods of using such determinations in selecting a therapeutic regimen for a cancer patient and in methods of treating cancer patients. In particular non-limiting embodiments, a plurality of tumor sites are evaluated and the composite effect of the genetic background on mTOR function is assessed.

The present invention relates to methods for the diagnosis and the treatment of familial thoracic aortic aneurysms caused by TGFB2 loss of function mutations. More particularly, the present invention relates to a method for determining whether a subject is predisposed to thoracic aortic aneurysms comprising detecting a TGFB2 loss of function mutation wherein the presence of the mutation indicated that the subject is predisposed to thoracic aortic aneurysms. The present invention also relates to a transforming growth factor beta-2 (TGF-β2) polypeptide for use in the prophylactic treatment of a subject who has been considered as predisposed to thoracic aortic aneurysms by the method of the invention (i.e. a subject having one TGB2 loss of function mutation according to the invention).

A banana plant comprising a genome comprising a loss of function mutation in a nucleic acid sequence encoding a component in an ethylene biosynthesis pathway of the banana is provided. Also provides is a method of increasing shelf-life of banana.

The present invention provides methods for determining the phenotype (e.g., gain-of-function or loss-of-function) of a mutation in an ion channel or receptor by using a dynamic voltage clamp. The invention also features methods of determining whether a mutation is a gain-of-function or loss-of-function mutation and treating a disease or disorder associated with the particular gain-of-function or loss-of-function mutation.

There is provided a method for determining the risk of colorectal cancer, including a step of detecting a loss-of-function mutation of a gene involved in interleukin (IL)-17 signaling in a colorectal epithelial tissue sample derived from a subject, in which a presence of the loss-of-function mutation indicates that the subject has a high risk of colorectal cancer.

A Solanaceous plant exhibiting a facultative parthenocarpy is provided. The plant comprises a loss-of-function mutation in a SlAGL6 gene and alternatively or additionally characterized by an average fruit weight/plant at least about the same as that of a non-parthenocarpic tomato of the same genetic background under fertilization permissive conditions of the non-parthenocarpic tomato. Also provided are methods of producing such plants and processed products produced from same.

A mutant, human ferroportin-1 protein and encoding nucleic acid are provided. The mutant ferroportin-1 protein has a deletion of valine 162 compared to wild-type ferroportin-1 protein. The mutant protein and nucleic acid may be useful in detection of a predisposition to iron overload disorders such as haemochromatosis. Furthermore, it is proposed that the valine 162 deletion is a loss-of-function mutation that may underlie iron overload disorders such as haemochromatosis. Therefore, methods of both diagnosis and treatment of haemochromatosis are provided.